CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows.
Open original source